| P50 | author | Aljoscha Neubauer | Q15448621 |
| | Benedicte Lescrauwaet | Q47159095 |
| P2093 | author name string | Benedicte Lescrauwaet | |
| | Annette Alaeus | |
| | Karin Sennfält | |
| | Bart Heeg | |
| | Per-Olof Thuresson | |
| P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| | Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention | Q28221041 |
| | Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial | Q34647153 |
| | Grade 4 Events Are as Important as AIDS Events in the Era of HAART | Q47386956 |
| | Costs of coronary heart disease and stroke: the case of Sweden. | Q50650715 |
| | The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life. | Q51116356 |
| | The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. | Q51943315 |
| | Cardiovascular disease risk profiles. | Q52461317 |
| | Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. | Q53608173 |
| | British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 | Q57180178 |
| | Treatment of HIV infection: Swedish recommendations 2009. | Q37634509 |
| | Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients | Q38959219 |
| | Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st | Q43208808 |
| | Utility assessments of opioid treatment for chronic pain | Q44345216 |
| | Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study | Q46121151 |
| | Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. | Q46492574 |
| | 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures | Q46973541 |
| | Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? | Q46974051 |
| P433 | issue | 4 | |
| P921 | main subject | Sweden | Q34 |
| | atazanavir | Q423467 |
| | lopinavir/ritonavir | Q3836750 |
| | lopinavir | Q422585 |
| | ritonavir | Q422618 |
| | atazanavir/ritonavir | Q39053473 |
| P304 | page(s) | 304-312 | |
| P577 | publication date | 2011-01-13 | |
| P1433 | published in | Infectious Diseases | Q7429961 |
| P1476 | title | Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden | |
| P478 | volume | 43 | |